Portal hypertension is a group of syndromes characterized by abnormal changes in the portal venous blood flow system, with rupture and bleeding of the esophagogastric fundus varices as the main complication. The treatment of portal hypertension is primarily directed at bleeding. The latest treatments include drug therapy such as carvedilol, and endoscopic therapy.
1. Drug therapy: In recent years, the latest research Carvedilol can be used for the treatment and prevention of portal hypertension. Carvedilol is a non-cardioselective vasodilatory beta-blocker and also has some anti-α1-adrenergic effects. Carvedilol is efficacious or superior to propranolol in controlling portal hypertension.
Secondly, vasopressin is the earliest clinical use of drugs to reduce portal hypertension, and currently vasopressin is gradually replaced by terlipressin. Growth inhibitors and long-acting growth inhibitor analogs are widely used in current clinical practice.
In addition, simvastatin, fenofibrate, sorafenib and other drugs are also hotspots in current research, and some studies have confirmed that they can reduce portal pressure by improving hepatic endothelial disorders, anti-oxidative stress or anti-fibrosis and other pathways.
2. Endoscopic treatment: In recent years, the technology of endoscopy has been developing rapidly, such as endoscopic esophageal variceal ligation and sclerosing agent injection are commonly used as the preferred methods to control and prevent esophageal variceal rupture and bleeding. And endoscopic esophagogastric variceal vein dissection is also the current cutting-edge technology.
Specifically, you can go to the hospital for treatment under the guidance of doctors to avoid delays.